Editorial: The use of real world data for regulatory purposes in the rare diseases setting.

Front Pharmacol

European Organisation for Rare Diseases (EURORDIS), Paris, France.

Published: November 2022

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730868PMC
http://dx.doi.org/10.3389/fphar.2022.1089033DOI Listing

Publication Analysis

Top Keywords

editorial real
4
real data
4
data regulatory
4
regulatory purposes
4
purposes rare
4
rare diseases
4
diseases setting
4
editorial
1
data
1
regulatory
1

Similar Publications

Background: Widespread digital transformation necessitates developing digital competencies for public health practice. Given work in 2024 to update Canada's public health core competencies, there are opportunities to consider digital competencies. In our previous research, we identified digital competency and training recommendations within the literature.

View Article and Find Full Text PDF

Consolidation ALK Tyrosine Kinase Inhibitor in Definitively Treated Unresectable Stage III ALK+ NSCLC: Can Real-World Data Inform Clinical Decision in the Absence of a LAURA-Type Designed Trial?

J Thorac Oncol

January 2025

Division of Hematology/Oncology, University of California Irvine School of Medicine, Orange/Irvine, California; Chao Family Comprehensive Cancer Center, Orange/Irvine, California; St. Marianna University School of Medicine, Kawasaki, Japan. Electronic address:

View Article and Find Full Text PDF

Introduction: Screening diabetic retinopathy (DR) for timely management can reduce global blindness. Many existing DR screening programs worldwide are non-digital, standalone, and deployed with grading retinal photographs by trained personnel. To integrate the screening programs, with or without artificial intelligence (AI), into hospital information systems to improve their effectiveness, the non-digital workflow must be transformed into digital.

View Article and Find Full Text PDF

Historically, it takes an average of 17 years to move new treatments from clinical evidence to daily practice. Given the highly effective treatments now available to prevent or delay kidney disease onset and progression, this is far too long. The time is now to narrow the gap between what we know and what we do.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!